CliffBio
small molecule

VIGAFYDE

VIGABATRIN

Loss of exclusivityJune 2043latest FDA-listed patent expiry
CompanyPyros Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIGAFYDE
Active ingredientVIGABATRIN
Strength100MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJune 2024
Marketing statusRX

Listed patents

PatentExpiresType
12576054June 2043product
12290499October 2042product
12016857August 2039product

More from Pyros Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIGAFYDE patent cliff — loss of exclusivity June 2043 | CliffBio